Stress-Induced Hyperglycaemia in Non-Diabetic Patients with Acute Coronary Syndrome: From Molecular Mechanisms to New Therapeutic Perspectives
Open accessThe DOI matches its Crossref record; 209 of the 216 references it cites were found in a registry or an index.
Abstract
Stress-induced hyperglycaemia (SIH) at hospital admission for acute coronary syndrome is associated with poor outcome, especially in patients without known diabetes. Nevertheless, insulin treatment in these subjects was not correlated with the reduction of mortality. This is likely due to the fact that SIH in the context of an acute coronary syndrome, compared to that in known diabetes, represents an epiphenomenon of other pathological conditions, such as adrenergic and renin-angiotensin system over-activity, hyperglucagonaemia, increase of circulating free fatty acids and pancreatic beta-cell dysfunction, which are not completely reversed by insulin therapy and so worsen the prognosis. Thus, SIH may be considered not only as a biomarker of organ damage, but also as an indicator of a more complex therapeutic strategy in these subjects. The aim of this review is to analyse the molecular mechanisms by which SIH may favour a worse prognosis in non-diabetic patients with acute coronary syndrome and identify new therapeutic strategies, in addition to insulin therapy, for a more appropriate treatment and improved outcomes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Stress hyperglycaemia without diabetes is associated with adverse in-hospital outcomes, and should be suspected in those with raised glucose levels during admission and normal HbA1c.19”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Angiotensin-neprilysin inhibition versus enalapril in heart failure
McMurray, J. J. V., Packer, M., Desai, A. S., Gong, J., Lefkowitz, M. P., Rizkala, A. R., Rouleau, J. L., Shi, V. C., Solomon, S. D., Swedberg, K., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1409077 · Cited by 6,957
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Oxidative stress and diabetic complications
Giacco, F., & Brownlee, M. (2010) · Circulation Research · doi:10.1161/circresaha.110.223545 · Cited by 5,461
Collet, J.-P., Thiele, H., Barbato, E., Barthélémy, O., Bauersachs, J., Bhatt, D. L., Dendale, P., Dorobantu, M., Edvardsen, T., Folliguet, T., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehaa575 · Cited by 5,037
Self-citationCosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G. T., Mitchell, L., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16451-9 · Cited by 2,558
Cited by
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Caturano, A., Galiero, R., Pafundi, P. C., Cesaro, A., Vetrano, E., Palmiero, G., Rinaldi, L., Salvatore, T., Marfella, R., Sardu, C., et al. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108959 · Cited by 73
Cui, K., Fu, R., Yang, J., Xu, H., Yin, D., Song, W., Wang, H., Zhu, C., Feng, L., Wang, Z., et al. (2022) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3562 · Cited by 68
“In addition, glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporters two inhibitors may significantly reduce the glucose levels and ischaemic cardiovascular events.(34,36)”
BackgroundLi, X., Yang, X., Dong, B.-B., & Liu, Q. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02577-z · Cited by 63
Lin, Z., Liang, X., Zhang, Y., Dai, Y., Zeng, L., Chen, W., Kong, S., He, P., Duan, C., & Liu, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01799-3 · Cited by 56
Higher Stress Hyperglycemia Ratio Is Associated With a Higher Risk of Stroke-Associated Pneumonia
Tao, J., Hu, Z., Lou, F., Wu, J., Wu, Z., Yang, S., Jiang, X., Wang, M., Huang, Q., & Ren, W. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.784114 · Cited by 49
“One possible reason was that acute hyperglycemia could promote oxidative stress, whereas chronic hyperglycemia could induce antioxidant defenses in tissues and cells (42).”
BackgroundFu, R., Cui, K., Yang, J., Xu, H., Yin, D., Song, W., Wang, H., Zhu, C., Feng, L., Wang, Z., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110241 · Cited by 46
Li, M., Chen, G., Feng, Y., & He, X. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.676892 · Cited by 46
Cardiovascular protective effects of GLP-1: a focus on the MAPK signaling pathway
Zhao, Y.-Y., Chen, L.-H., Huang, L., Li, Y., Chen, Y., Zhu, Y., Qu, S., & Zhang, C. (2021) · Biochemistry and Cell Biology · doi:10.1139/bcb-2021-0365 · Cited by 32
Bellis, A., Gioia, G. D., Mauro, C., Mancusi, C., Barbato, E., Izzo, R., Trimarco, B., & Morisco, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10132968 · Cited by 29
Self-citationYu, Q., Fu, Q., Ma, X., Wang, H., Xia, Y., Chen, Y., Li, P., Li, Y., & Yanqing, W. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02684-x · Cited by 27
“In addition, the hyperactivity of the adrenergic and renin-angiotensin systems, hyperglucagonemia, and elevated circulating free fatty acids associated with high SHR are not fully reversible by insulin therapy, further contributing to poor patient outcomes [51].”
Huang, H., Liu, J., Li, Q., Qiao, L., Chen, S., Kang, Y. M., Lu, X., Zhou, Y., He, Y., Chen, J., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117306 · Cited by 23
Hu, X., Feng, D., Zhang, Y., Wang, C., Chen, Y., Niu, G., Zhou, Z., Zhao, Z., Zhang, H., Wang, M., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02160-y · Cited by 25
“Stress-induced hyperglycemia is a physiological response of the body to various critical situation aimed at restoring metabolic balance, even in patients without diabetes [33].”
BackgroundZhang, S., Shen, H., Wang, Y., Ning, M., Zhou, J., Liang, X., Chang, Y. S., Gao, W., & Li, T. (2025) · European journal of medical research · doi:10.1186/s40001-025-02281-4 · Cited by 22
Zhang, X., Wang, X., Xu, L., Liu, J., Ren, P., & Wu, H. (2023) · European journal of medical research · doi:10.1186/s40001-023-01027-4 · Cited by 23
“Increased local and systemic inflammatory responses [79], altered platelet function and thrombo-fibrinolytic system [80], increased oxidative stress [81], endothelial dysfunction [82], arrhythmic ten-dencies [83], and impaired myocardial contractility [84], all ultimately lead to increased…”
BackgroundCui, K., Fu, R., Yang, J., Xu, H., Yin, D., Song, W., Wang, H., Zhu, C., Feng, L., Wang, Z., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.898384 · Cited by 18
Lian, L., Xue, W.-H., Lu, J.-J., & Zheng, R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1383993 · Cited by 14
Shen, H., Wang, S., Zhang, C., Gao, W., Cui, X., Zhang, Q., Lang, Y., Ning, M., & Li, T. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03208-9 · Cited by 13
“Additionally, in the presence of DM, there may be a “preconditioning phenomenon” that increases antioxidant defenses, and protects tissues from oxidative stress response caused by acute hyperglycemia [28].”
BackgroundZhen, C., Wei, C., Chen, W., Fan, H., Lin, Z., Zeng, L., Lin, Z., He, W., Li, Y., Peng, S., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1132685 · Cited by 12
Li, K., Yang, X., Li, Y., Xu, G., & Ma, Y. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02128-y · Cited by 11
“SIH in patients with ACS may result from pancreatic β-cell dysfunction and insulin resistance [18, 19].”
BackgroundXu, C., Yu, B., Zhao, X., Lin, X., Tang, X., Liu, Z., Gao, P., Ge, J., Wang, S., & Li, L. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.803532 · Cited by 11
“For example, an increased FPG level could be explained by hyperglycemia under the stress of ACS, known as stress induced hyperglycemia (SIH) (18, 19), whereas the elevation of UA is possibly due to the fact that UA level is closely related to oxidative stress, endothelial dysfunction, inflammation, and vasoconstrictio…”
BackgroundNusca, A., Piccirillo, F., Bernardini, F., Filippis, A. D., Coletti, F., Mangiacapra, F., Ricottini, E., Melfi, R., Gallo, P., Cammalleri, V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137261 · Cited by 14
Beta Blockers can Mask not only Hypoglycemia but also Hypotension
Koracevic, G. P., Mićić, S., Stojanović, M., Radovanović, R. V., Pavlović, M., Kostić, T. L., Djordjevic, D. B., Antonijevic, N. M., Koraćević, M., Atanaskovic, V., et al. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220421135523 · Cited by 11
Liu, S., Song, C., Cui, K., Bian, X., Wang, H., Fu, R., Zhang, R., Yuan, S., & Dou, K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110815 · Cited by 12
Liu, T., Wang, L., Zhang, H., & Dai, Q. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-04831-4 · Cited by 7
“This increased insulin resistance worsens hyperglycaemia, creating a vicious cycle that disrupts myocardial recovery and increases the risk of death [28, 35].”
Bantidos, M. G., Stalikas, N., Fyntanidou, B., Skalidis, I., Arvanitaki, A., Kofos, C., Apostolopoulou, A., Γιαννόπουλος, Γ., & Karagiannidis, E. (2025) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2025.2561068 · Cited by 9
“Beyond being a metabolic byproduct of the stress response, SIH may also exacerbate myocardial injury by fostering oxidative stress and endothelial dysfunction, mechanisms that directly impede myocardial healing [8].”
Reddy, B. R., Sreenivasamurthy, L., Pal, J., Saseedharan, S., Sathe, P., Maheshwari, A., Canday, E., Hazarika, B. G., Patil, A., Malve, H., et al. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0571 · Cited by 7
Guo, J., Jia, J., Zhang, J., Liu, X., Li, G., Zhao, X., & Liu, Y. (2023) · Cerebrovascular Diseases · doi:10.1159/000528068 · Cited by 8
“In addition, patients with prior diabetes are more likely to receive antidiabetic agents and insulin, which may reduce cerebral lactic acidosis and other harmful metabolic changes in the brain [23].”
Kaziród-Wolski, K., Zając, P., Zabojszcz, M., Kołodziej, A., Sielski, J. K., & Siudak, Z. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11185394 · Cited by 8
“It has been shown that stress, through the generation of hyperglycemia, in patients without previously diagnosed diabetes, was associated with a poorer prognosis in patients admitted to the hospital for ACS [42] and, therefore, may have influenced the different courses of UA.”
BackgroundLi, Y., Shen, N., Xie, E., Guo, Z., Ye, Z., Yang, K., Li, X., Gao, Y., & Zheng, J. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108895 · Cited by 6
Guo, F.-S., Dou, J., Wang, J.-X., Guo, C. Y., Wu, R., Sun, X.-L., Hu, Y.-W., & Wei, J. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01671-2 · Cited by 6
“Moreover, excess glucose will be preferentially taken up and utilized by cardiomyocytes, thereby imposing an additional metabolic burden on the heart [46].”
Wu, J., Liu, J., Yuan, Z., Tang, S., Zhang, W., Xiang, Y., Chen, J., Lin, Q., Guo, W., He, Y., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01521-7 · Cited by 6
Wang, L., Xu, Y., Chen, L., & Zhang, H. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1540794 · Cited by 7
Chen, Y., Liu, A., Zhang, L., Wan, X., Jiao, J., & Sun, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-18058-y · Cited by 5
Boğa, E. (2025) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1602462 · Cited by 4
Pandey, R. K., Lwin, B. B., Vashishta, A., Nishat, S., Mueka, I. N., Hassan, M. U., & Nwosu, M. (2024) · Cureus · doi:10.7759/cureus.66365 · Cited by 3
“There may be pancreatic B cell dysfunction and tissue insulin resistance contributing to hyperglycemia [19,20].”
BackgroundInfluentialHu, B., Yang, Z., Lu, Y., Huang, S., Huang, X., Wang, C., & Cai, J. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112301 · Cited by 3
Linee guida ESC 2023 per il trattamento delle malattie cardiovascolari nei pazienti diabetici
Marx, N., Federici, M., Schütt, K. S., Müller‐Wieland, D., Ajjan, R., Antunes, M. J., Christodorescu, R., Crawford, C. A., Angelantonio, E. D., Eliasson, B., et al. (2024) · Giornale Ialiano di Cardiologia · doi:10.1714/4162.41558 · Cited by 6
Tang, W., Xiao-min, N., Yao, W., Wang, W., Lv, Q., Ding, W., & He, R. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1340435 · Cited by 3
Rui, F. U., Zhu, Y., Cui, K., Yang, J., Xu, H., Yin, D., Song, W., Wang, H., Zhu, C., Feng, L., et al. (2024) · 老年心脏病学杂志:英文版 · doi:10.26599/1671-5411.2024.05.008 · Cited by 2
Luo, Y., Xiao-min, N., Yao, W., Wang, W., Li, Y., Lv, Q., Ding, W., & Tang, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-78343-0 · Cited by 3
Thu, N. H., Nien, L., Dung, B., Vu, V., Thanh, N., & Thinh, N. (2025) · Medical Archives · doi:10.5455/medarh.2025.79.473-480 · Cited by 2
“Concurrent activation of alpha-2 adrenergic receptors suppresses pancreatic beta-cell insulin secretion, resulting in a disproportionate increase in plasma glucose relative to circulating insulin (21).”
He, S., Wang, Y., Li, H., Zheng, W., & Yang, S. (2026) · European journal of medical research · doi:10.1186/s40001-026-04106-4 · Cited by 1
Xin, Y., Lyu, S., Wang, Y., & Yang, Y. (2026) · International Journal of Surgery · doi:10.1097/js9.0000000000005016 · Cited by 1
Mei, C., Chen, L., Shi, Q., Guo, X., Yang, Y., Wang, Q., Han, B., Fan, T., Chen, J., & Tao, T. (2026) · BMC Neurology · doi:10.1186/s12883-026-04802-y · Cited by 1
“…unclear but may involve the following: (a) direct mechanisms: chronic hyperglycemia induces adaptive antioxidant defenses in tissues and cells [35], such as downregulating aldose reductase expression to mitigate oxidative stress [36]; (b) indirect or mediating mechanisms: while hyperglycemia…”
Ma, X., Duan, J., Cheng, Y., Li, W., Liang, C., Yang, T., Liu, J., Mi, Y., Du, S., Xue, F., et al. (2026) · Mediators of Inflammation · doi:10.1155/mi/9595535 · Cited by 1
“Thus, SIH may represent a heterogeneous pathological condition, and deep understanding on its role in affecting stroke outcomes is urgently needed in clinical practice to expand our option to address the SIH issue [9, 10].”
Khan, J., Khan, M. F., Khan, K., Gul, S., Ullah, Q., & Qadus, N. (2026) · Pakistan Heart Journal · doi:10.47144/phj.v59i2.3551 · Cited by 1
“While fasting and random plasma glucose measurements are commonly used during hospitalization, HbA1c provides an estimate of chronic glycemic exposure and helps reduce misclassification related to stress-induced hyperglycemia [7,8].”
Wei, F., & Wei, H. A. N. (2023) · Minerva Pediatrics · doi:10.23736/s2724-5276.23.07228-2 · Cited by 1
Hakim, D. I., Qhabibi, F. R., Yusuf, M. F. R. H., Effendi, A. B., & Prasetya, I. (2025) · Next research. · doi:10.1016/j.nexres.2025.100495 · Cited by 1
Li, K., Yang, X., Liu, J., Chen, L., Xiao, H., Yang, C., Chen, Y., Li, Y., Wen, J., Ma, Y., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4206522/v1
Hiperglicemia como factor de riesgo de mortalidad hospitalaria en infarto de miocardio
Barrantes-Alarcón, C., Fernández-Coronado, R., & Olórtegui‐Yzú, A. (2024) · Revista de la Facultad de Medicina Humana · doi:10.25176/rfmh.v24i1.6341
ACİL SERVİSTE PARASETAMOL ZEHİRLENMESİNE YAKLAŞIM
BARUT, K. (2025) · Bidge Yayınları eBooks · doi:10.70269/10.70269/7495199936
DOĞAN, Ö. (2025) · Bidge Yayınları eBooks · doi:10.70269/10.70269/4663331296
USE OF WEARABLE DEVICES IN HEART FAILURE
Erenler, A. K. (2025) · Bidge Yayınları eBooks · doi:10.70269/10.70269/2217163844
DETERMINING THE FIRST AID KNOWLEDGE LEVELS OF CABIN CREW: THE CASE OF TURKEY
Baş, Y. Ç., ECEVİT, E. D., & CEVHER, E. (2025) · Bidge Yayınları eBooks · doi:10.70269/10.70269/2571512697
Liu, Y., Yang, Y., Li, Y., & Yang, X. (2025) · BMC Geriatrics · doi:10.1186/s12877-025-06116-z
“Bellis’s study demonstrated that patients with stress-induced hyperglycemia generally have a poorer prognosis compared to those with diabetes-related hyperglycemia, a finding that aligns with Guo’s research [48–50].”
Zhao, Q., Che, W.-Q., Sheng, Z., Wang, F., An, S.-Y., Zhang, Z., Gao, Y.-X., Liang, T., & Zheng, J. (2025) · BMC Cardiovascular Disorders · doi:10.1186/s12872-025-05391-3
“Notably, stress-induced hyperglycemia during CAHD onset has been shown to correlate with poor cardiovascular outcomes, particularly in patients without a pre-existing diabetes mellitus diagnosis at admission [8–11].”
Chen, H., Wang, X., Chen, H., & Sun, Y. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1692103
“Similar observations were reported in previous studies, where stress hyperglycemia predicted poor outcomes more strongly in non-diabetic than diabetic patients, reinforcing the need for future individual patient data (IPD) meta-analyses to delineate such interactions more precisely (43).”
Shen, H., Wang, S., Zhang, C., Gao, W., Cui, X., Zhang, Q., Lang, Y., Ning, M., & Li, T. (2024) · Figshare · doi:10.6084/m9.figshare.26585802
Lin, Z., Liang, X., Zhang, Y., Dai, Y., Zeng, L., Chen, W., Kong, S., He, P., Duan, C., & Liu, Y. (2024) · Figshare · doi:10.6084/m9.figshare.26579708
Hu, X., Feng, D., Zhang, Y., Wang, C., Chen, Y., Guannan, N., Zhou, Z., Zhao, Z., Zhang, H., 王墨扬, et al. (2024) · Figshare · doi:10.6084/m9.figshare.25237356
Deng, L., li, X., Ran, J., Du, C., Chen, Y., Deng, W., Wang, M., & Yang, G. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02108-0
“This phenomenon, commonly observed in critically ill patients, is attributed to the activation of stress hormone pathways (e.g., corticosteroids and catecholamines), alongside increased hepatic glucose production and glycogenolysis [30, 32].”
Xu, H., Lv, X., Xia, Y., Niu, H., Li, J., & He, P. (2026) · BMC Infectious Diseases · doi:10.1186/s12879-026-13008-z
“This response may enhance antioxidant defenses and protect tissues from oxidative stress [26].”
Du, Y., Lai, G., Bai, S., Huang, X., Sun, C., Wei, X., Han, M., Mao, Y., Shi, S., Chen, L., et al. (2026) · Asian Journal of Surgery · doi:10.1016/j.asjsur.2026.02.164
Hou, X., Zhou, X., Wang, W., Chen, X., Li, Y., Gong, Z., Yang, Y., & Zhang, X. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1703043
“This involves the activation of the hypothalamic-pituitary-adrenal (HPA) axis, the sympathetic nervous system (SNS), and the renin-angiotensin-aldosterone system (RAAS), leading to elevated levels of insulin-inhibiting hormones, insufficient insulin, and acute insulin resistance (IR) (34–36).”
Khoroshun, E. M., Seliukova, N. Y., Nehoduiko, V. V., Макаров, Д., Бойко, М., Перець, О. В., & Misiura, K. V. (2026) · PROBLEMS OF ENDOCRINE PATHOLOGY · doi:10.21856/j-pep.2026.1.07
ĐÁNH GIÁ ĐỀ KHÁNG INSULIN TRONG THỰC HÀNH LÂM SÀNG: TỔNG QUAN CÁC PHƯƠNG PHÁP VÀ ĐỊNH HƯỚNG ỨNG DỤNG
Thư, N. N. M. (2026) · TẠP CHÍ KHOA HỌC TRƯỜNG ĐẠI HỌC QUỐC TẾ HỒNG BÀNG · doi:10.59294/hiujs.khtt.2026.005
Glucosa en las primeras 24horas de UCI y mortalidad a 90 días en pacientes con lesión renal aguda
Tirado, A. G. (2026) · Acta Colombiana de Cuidado Intensivo · doi:10.1016/j.acci.2026.100644
Ismail, M. R., Hassan, W. U., Siddiqi, F. A., Sharif, D. A., Ashraf, T., & Masood, F. (2026) · Pakistan Armed Forces Medical Journal · doi:10.51253/pafmj.v76i6.13316
Krljanac, G., Ašanin, M., Bogdanović, J. M., Savić, L., Lukač, S. S., Stankovic, S. D., Rasulić, I., Popović, L., Polovina, M. M., Petakov, A., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10741294/v1
Hysenaj, K., Kapaj, A., Stena, R., Bani, B., Dybeli, E., Drizaj, E., & Hysenaj, A. (2026) · Malque Health · doi:10.31893/health.2027010
Metadata
- Authors
- Bellis, A., Mauro, C., Barbato, E., Ceriello, A., Cittadini, A., & Morisco, C.
- Affiliations
- Ospedale Antonio Cardarelli (IT)
- University of Naples Federico II (IT)
- MultiMedica (IT)
- Corresponding author
- Morisco, Carmine
- ORCID
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2021-01-14
- Volume
- 22
- Issue
- 2
- Pages
- 775
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC7828822
- OpenAlex
- W3121056265
- Cited by
- 61
- References
- 216
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 14 · 2023: 10 · 2022: 7 · 2021: 4
- FWCI
- 1.34
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- stress hyperglycemia, acute coronary syndrome, non-diabetic patients, insulin therapy, prognosis, adrenergic system, renin-angiotensin system, hyperglucagonaemia, free fatty acids, beta-cell dysfunction, molecular mechanisms, treatment options
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Adrenergic beta-Antagonists, Angiotensin-Converting Enzyme Inhibitors, Animals, Humans, Hyperglycemia, Hypoglycemic Agents, Insulin, Stress, Psychological, Acute Coronary Syndrome, Dipeptidyl-Peptidase IV Inhibitors, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.